NOX - Noxopharm Limited - Strawman: ASX share price, valuation, research and discussion

Top member reports

Company Report

Last edited 4 years ago

ranked

#135

Performance (52m)

-15.4% pa

Followed by

155

Straws

Sort by:

Recent

Content is delayed by one month. Upgrade your membership to unlock all content. Click for membership options.

Become a member

#Announcement 15/2/21

stale

Added 4 years ago

Cancer Conference Presentation Confirms Potential Breakthrough For Stage 4 Prostate Cancer Patients

• Drug combination NOX66 (Veyonda?) and 177lutetium-PSMA-617 delivers high response rates in heavily pre-treated men with end-stage prostate cancer

• Median Overall Survival of 19.7 months a potential breakthrough in the treatment of end-stage prostate cancer

Noxopharm Limited